Physician profile
Barry Glanzman
NPI 1598793937
$3,142.90
in general payments reported to CMS, 2019-2025
27 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $146 · 2021: $169 · 2022: $106 · 2023: $781 · 2024: $1,425 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.20 |
| Education | $133.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.90 | 2019-2025 | |
| Qol Medical, LLC | $358.22 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.09 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $227.22 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $209.78 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $189.58 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $155.41 | 2019-2024 | Injectafer |
| Celltrion USA INC. | $133.09 | 2024 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $132.26 | 2024 | Voquezna |
| Celgene Corporation | $119.79 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $63.85 | 2024 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $63.17 | 2023-2024 | Entyvio |
| Supernus Pharmaceuticals, INC. | $56.61 | 2023-2024 | Qelbree, Qelbree |
| Allergan, INC. | $53.97 | 2019 | |
| Nestle Healthcare Nutrition INC. | $50.03 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $47.72 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $44.23 | 2021-2024 | |
| Exact Sciences Corporation | $42.29 | 2024 | Cologuard Collection Kit |
| Neos Therapeutics, LP | $32.52 | 2024 | Adzenys Xr-Odt |
| Genzyme Corporation | $28.38 | 2024 | |
| Ironwood Pharmaceuticals, INC | $22.05 | 2023 | Linzess |
| Orphalan INC | $21.76 | 2024 | Cuvrior |
| Intra-Sana Laboratories | $17.20 | 2022 | |
| Braintree Laboratories, INC. | $17.12 | 2019 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.87 | 2023 | Rytary |
| Thd America, INC. | $12.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Glanzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.